» Articles » PMID: 17921332

Inducible and Myocyte-specific Inhibition of PKCalpha Enhances Cardiac Contractility and Protects Against Infarction-induced Heart Failure

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Mice null for the gene encoding protein kinase Calpha (Prkca), or mice treated with pharmacologic inhibitors of the PKCalpha/beta/gamma isoforms, show an augmentation in cardiac contractility that appears to be cardioprotective. However, it remains uncertain if PKCalpha itself functions in a myocyte autonomous manner to affect cardioprotection in vivo. Here we generated cardiac myocyte-specific transgenic mice using a tetracycline-inducible system to permit controlled expression of dominant negative PKCalpha in the heart. Consistent with the proposed function of PKCalpha, induction of dominant negative PKCalpha expression in the adult heart enhanced baseline cardiac contractility. This increase in cardiac contractility was associated with a partial protection from long-term decompensation and secondary dilated cardiomyopathy after myocardial infarction injury. Similarly, Prkca null mice were also partially protected from infarction-induced heart failure, although the area of infarction injury was identical to controls. Thus, myocyte autonomous inhibition of PKCalpha protects the adult heart from decompensation and dilated cardiomyopathy after infarction injury in association with a primary enhancement in contractility.

Citing Articles

Acute protein kinase C beta inhibition preserves coronary endothelial function after cardioplegic hypoxia/reoxygenation.

Kant S, Xing H, Liu Y, Harrington E, Sellke F, Feng J JTCVS Open. 2023; 15:242-251.

PMID: 37808045 PMC: 10556935. DOI: 10.1016/j.xjon.2023.06.014.


Adrenergic Regulation of Calcium Channels in the Heart.

Papa A, Kushner J, Marx S Annu Rev Physiol. 2021; 84:285-306.

PMID: 34752709 PMC: 9573788. DOI: 10.1146/annurev-physiol-060121-041653.


Attenuating persistent sodium current-induced atrial myopathy and fibrillation by preventing mitochondrial oxidative stress.

Avula U, Dridi H, Chen B, Yuan Q, Katchman A, Reiken S JCI Insight. 2021; 6(23).

PMID: 34710060 PMC: 8675199. DOI: 10.1172/jci.insight.147371.


Use of Proximity Labeling in Cardiovascular Research.

Kushner J, Papa A, Marx S JACC Basic Transl Sci. 2021; 6(7):598-609.

PMID: 34368510 PMC: 8326230. DOI: 10.1016/j.jacbts.2021.01.005.


Probing ion channel neighborhoods using proximity proteomics.

Redel-Traub G, Liu G, Marx S, Kushner J Methods Enzymol. 2021; 654:115-136.

PMID: 34120710 PMC: 9569177. DOI: 10.1016/bs.mie.2021.01.027.


References
1.
Sanbe A, Gulick J, Hanks M, Liang Q, Osinska H, Robbins J . Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res. 2003; 92(6):609-16. DOI: 10.1161/01.RES.0000065442.64694.9F. View

2.
Vlahos C, McDowell S, Clerk A . Kinases as therapeutic targets for heart failure. Nat Rev Drug Discov. 2003; 2(2):99-113. DOI: 10.1038/nrd1009. View

3.
Hambleton M, Hahn H, Pleger S, Kuhn M, Klevitsky R, Carr A . Pharmacological- and gene therapy-based inhibition of protein kinase Calpha/beta enhances cardiac contractility and attenuates heart failure. Circulation. 2006; 114(6):574-82. PMC: 2707825. DOI: 10.1161/CIRCULATIONAHA.105.592550. View

4.
Dorn 2nd G, Molkentin J . Manipulating cardiac contractility in heart failure: data from mice and men. Circulation. 2004; 109(2):150-8. DOI: 10.1161/01.CIR.0000111581.15521.F5. View

5.
Pass J, Gao J, Jones W, Wead W, Wu X, Zhang J . Enhanced PKC beta II translocation and PKC beta II-RACK1 interactions in PKC epsilon-induced heart failure: a role for RACK1. Am J Physiol Heart Circ Physiol. 2001; 281(6):H2500-10. DOI: 10.1152/ajpheart.2001.281.6.H2500. View